Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC

Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC

Show other versions (1)

While screening and early detection have reduced mortality from prostate cancer, castration-resistant disease (CRPC) is still incurable. Here, we report that combined EZH2/HDAC inhibitors potently kill CRPCs and cause dramatic tumor regression in aggressive human and mouse CRPC models. Notably, EZH2...

Full description

Bibliographic Details
Main Authors: Amy E. Schade, Ryan Kuzmickas, Carrie L. Rodriguez, Kaia Mattioli, Miriam Enos, Alycia Gardner, Karen Cichowski
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-04-01
Series:PLoS Biology
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138213/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138213/?tool=EBI

Similar Items